Evidence map›Paper›PMID 32060146›Full record

ArticleCancer research2020

Blocking SHH/Patched Interaction Triggers Tumor Growth Inhibition through Patched-Induced Apoptosis.

Pierre-Antoine Bissey, Pauline Mathot, Catherine Guix, Mélissa Jasmin, Isabelle Goddard, Clélia Costechareyre, Nicolas Gadot, Jean-Guy Delcros, Sachitanand M Mali, Rudi Fasan and 5 more

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Pierre-Antoine BisseyApoptosis, Cancer and Development Laboratory-Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut Convergence PLASCAN, Cancer Research Center of Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France.ORCID 0000-0002-9192-3315
Pauline MathotApoptosis, Cancer and Development Laboratory-Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut Convergence PLASCAN, Cancer Research Center of Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France.
Catherine GuixApoptosis, Cancer and Development Laboratory-Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut Convergence PLASCAN, Cancer Research Center of Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France.
Mélissa JasminApoptosis, Cancer and Development Laboratory-Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut Convergence PLASCAN, Cancer Research Center of Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France.ORCID 0000-0002-3018-917X
Isabelle GoddardApoptosis, Cancer and Development Laboratory-Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut Convergence PLASCAN, Cancer Research Center of Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France.
Clélia CostechareyreApoptosis, Cancer and Development Laboratory-Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut Convergence PLASCAN, Cancer Research Center of Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France.
Nicolas GadotDepartment of Translational Research and Innovation, Anapath, Centre Léon Bérard, Lyon.
Jean-Guy DelcrosApoptosis, Cancer and Development Laboratory-Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut Convergence PLASCAN, Cancer Research Center of Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France.ORCID 0000-0002-9593-4046
Sachitanand M MaliDepartment of Chemistry, University of Rochester, Rochester, New York.
Rudi FasanDepartment of Chemistry, University of Rochester, Rochester, New York.
André-Patrick ArrigoApoptosis, Cancer and Development Laboratory-Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut Convergence PLASCAN, Cancer Research Center of Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France.
Robert DanteApoptosis, Cancer and Development Laboratory-Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut Convergence PLASCAN, Cancer Research Center of Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France.
Gabriel IchimCancer Cell death Lab, Cancer Reasearch Center of Lyon (CRCL), LabEx DEVweCAN, Institut Convergence PLASCAN, Université de Lyon, Centre Léon Bérard, Lyon, France.
Patrick Mehlen *Apoptosis, Cancer and Development Laboratory-Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut Convergence PLASCAN, Cancer Research Center of Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. patrick.mehlen@lyon.unicancer.fr joanna.fombonne@lyon.unicancer.fr.
Joanna Fombonne *Apoptosis, Cancer and Development Laboratory-Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut Convergence PLASCAN, Cancer Research Center of Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. patrick.mehlen@lyon.unicancer.fr joanna.fombonne@lyon.unicancer.fr.
Université Claude Bernard Lyon 1 · FRUniversity of Rochester · USCentre Léon Bérard · FR

Funding

Macrocyclic Peptide Modulators of Protein FunctionR01GM134076 · NIGMS · UNIVERSITY OF TEXAS DALLAS · PI FASAN, RUDI · 2019 to 2022
$1.2M
Orbitrap Fusion Lumos Mass Spectrometer for UR Proteomics ResearchS10OD025242 · OD · UNIVERSITY OF ROCHESTER · PI GHAEMMAGHAMI, SINA · 2018 to 2018
$1.1M
NIGMS NIH HHS R01 GM134076NIH HHS S10 OD025242
6 · The paper itself

Abstract

The Sonic Hedgehog (SHH) pathway plays a key role in cancer. Alterations of SHH canonical signaling, causally linked to tumor progression, have become rational targets for cancer therapy. However, Smoothened (SMO) inhibitors have failed to show clinical benefit in patients with cancers displaying SHH autocrine/paracrine expression. We reported earlier that the SHH receptor Patched (PTCH) is a dependence receptor that triggers apoptosis in the absence of SHH through a pathway that differs from the canonical one, thus generating a state of dependence on SHH for survival. Here, we propose a dual function for SHH: its binding to PTCH not only activates the SHH canonical pathway but also blocks PTCH-induced apoptosis. Eighty percent, 64%, and 8% of human colon, pancreatic, and lung cancer cells, respectively, overexpressed SHH at transcriptional and protein levels. In addition, SHH-overexpressing cells expressed all the effectors of the PTCH-induced apoptotic pathway. Although the canonical pathway remained unchanged, autocrine SHH interference in colon, pancreatic, and lung cell lines triggered cell death through PTCH proapoptotic signaling.

Indexed as

AnimalsApoptosisCell Line, TumorCell ProliferationChick EmbryoHedgehog ProteinsHeterograftsHumansMiceNeoplasmsPatched ReceptorsSignal TransductionZebrafishHedgehog ProteinsPatched Receptors

Identifiers

PMID32060146
PMCPMC7231656
OpenAlexW3005539560

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.